We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Fed. Circ. Affirms Nix Of Novartis Dementia Patch Patents

Law360, New York (April 4, 2017, 4:31 PM EDT) -- The Federal Circuit on Tuesday upheld a Patent Trial and Appeal Board decision that the challenged claims of two Novartis patents covering the dementia patch Exelon were invalid as obvious, affirming a win for accused infringer Noven Pharmaceuticals.

The three-judge panel found that the PTAB had properly concluded that the asserted claims of U.S. Patent Nos. 6,316,023 and 6,335,031 would have been obvious from several different combinations of prior art references. The court rejected Novartis AG’s argument that the PTAB's decision could not stand because the...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Novartis AG v. Noven Pharmaceuticals Inc.


Case Number

16-1678

Court

Appellate - Federal Circuit

Nature of Suit

Date Filed

March 10, 2016


Case Title

Novartis AG v. Noven Pharmaceuticals Inc.


Case Number

16-1679

Court

Appellate - Federal Circuit

Nature of Suit

Date Filed

March 10, 2016

Law Firms

Companies

Government Agencies

Patents

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.